The Role of Microglia in AD Pathogenesis and Treatment
About the Research Project
Program
Award Type
Standard
Award Amount
$99,892
Active Dates
April 01, 2004 - March 31, 2006
Grant ID
A2004274
Mentor(s)
Cynthia Lemere, PhD, Harvard Medical School, Brigham and Women's Hospital
Summary
One of the hallmarks of Alzheimer’s disease (AD) is the accumulation of a protein called beta-amyloid (Aß) in the brain. This protein is formed throughout life, but as some individuals age, the protein begins to accumulate in aggregates called plaques. Surrounding the Aß plaques in the brain is an area of inflammation that involves the immune cells of the brain, called the microglia. Microglia produce both noxious substances that can increase the damage to the brain caused by Aß and helpful substances that help brain cells maintain normal function. Dr. Seabrook is studying the effects of suppressing microglia on the formation of plaques in mice that have been engineered to produce an abnormal human form of Aß in their brain. These experiments will help elucidate the basic role of microglia in the formation of Aß. The role of microglia during vaccination will also be examined, which could lead to a better understanding of their role in this promising therapeutic area.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD